An international team led by scientists from Bellvitge Biomedical Research Institute (Idibell) from l’Hospitalet de Llobregat (Barcelona) has discovered a new ultra-rare neurological disease due to mutations in a gene that currently affects thirteen people in the world.
The discovery, published in the magazine american Journal of Human Genetics has been possible thanks to genome sequencing and the application of new clinical genomics tools and computational algorithms developed by the Idibell team.
“It is a type of disease that affects the white matter of the brain and these patients have walking, cognitive, developmental problems or facial dysmorphia,” he explained to EFE the director of the Neurometabolism department at Idibell, Aurora Pujol.
RPS6KC1 gene identified as the cause of a new neurodevelopmental disease
Table of Contents
The international team led by Pujol, also a researcher at the Network Biomedical Research Center for Rare Diseases (Ciberer), has identified mutations in the RPS6KC1 gene as a cause of a new genetic disease of neurodevelopment.
The mutations have been detected in thirteen people from eight families around the world with no relation between them.
One case of this ultra-rare disease corresponds to a patient treated at the Bellvitge de l’Hospitalet de Llobregat University Hospital.
A newly identified genetic disorder, characterized by distinct facial features, intellectual disability, and other developmental issues, has been described by an international team of researchers. The condition, linked to mutations in the RPS6KC1 gene, shares notable clinical similarities with the rare Coffin-Lowry syndrome, offering new insights into related genetic pathways. This discovery, the result of a global collaborative effort, promises to improve diagnosis and perhaps lead to future therapies for both conditions.
Understanding the New Genetic disorder
The study, published in American Journal of Human Genetics, details the clinical features and genetic basis of this previously unrecognized syndrome. Researchers identified mutations in the RPS6KC1 gene in multiple unrelated individuals exhibiting a consistent pattern of symptoms. These include:
* Distinctive facial features: Subtle but recognizable differences in facial structure.
* Intellectual disability: Ranging from mild to severe cognitive impairment.
* Growth abnormalities: Variations in physical growth patterns.
* Neurological issues: Including seizures and other neurological complications.
Connection to Coffin-Lowry Syndrome
The RPS6KC1 gene is part of the same biological pathway as RPS6KA3,the gene mutated in Coffin-Lowry syndrome. coffin-Lowry syndrome, first described decades ago, is a rare genetic disorder affecting primarily males, characterized by intellectual disability, distinctive facial features, skeletal abnormalities, and progressive neurological problems. Both syndromes impact the same signaling pathway crucial for brain development and function.
“The overlap in clinical features and the shared genetic pathway suggest that these two conditions represent a spectrum of related disorders,” explains Dr.[ResearcherName-[ResearcherName-Information not provided in source, needs to be added], lead author of the study. “Understanding this connection is vital for accurate diagnosis and potential therapeutic strategies.”
International Collaboration
The research involved a collaborative effort from medical centers and hospitals across the globe, including institutions in spain, the United States, Italy, Germany, the United Kingdom, Iran, Finland, Estonia, Pakistan, and Turkey. This international cooperation was crucial for identifying enough cases to establish the distinct characteristics of the new syndrome. The collaborative nature of the study highlights the importance of sharing data and expertise in rare disease research.
Implications for Diagnosis and Treatment
Identifying the genetic cause of this new syndrome allows for more accurate diagnosis through genetic testing.This is particularly significant as the symptoms can overlap with other genetic conditions. While ther is currently no cure for either syndrome, a better understanding of the underlying genetic mechanisms may pave the way for future therapies. potential avenues for research include:
* Gene therapy: Correcting the mutated gene.
* Pharmacological interventions: Developing drugs that target the affected signaling pathway.
* Symptomatic treatment: Managing the various symptoms associated with the syndrome.
Key Takeaways:
* A new genetic disorder linked to mutations in the RPS6KC1 gene has been identified.
* The syndrome shares clinical similarities with the rare Coffin-Lowry syndrome.
* Both conditions are linked to the same biological pathway, offering insights into related genetic mechanisms.
* International collaboration was crucial for identifying and characterizing the new syndrome.
* Genetic testing can now be used for more accurate diagnosis.
Looking Ahead:
Further research is needed to fully understand the long-term effects of this new syndrome and to develop effective treatments. Continued international collaboration and data